Alexandria Real Estate Equities, Inc. signs Bristol-Myers Squibb to 208,000 s/f at 100 Binney Street - a new 431,500 s/f ground-up development in Cambridge

According to Alexandria Real Estate Equities, Inc., Bristol-Myers Squibb, a global biopharmaceutical company, will establish a research and development center at the Alexandria Center at Kendall Sq. (ACKS). As the anchor tenant in Alexandria's newest ground-up development at 100 Binney St., Bristol-Myers Squibb will lease 208,000 s/f in a world-class, sustainable office/laboratory facility that has a total of 431,500 s/f. The project began construction in July and is expected to be delivered in the fourth quarter of 2017. The decision by Bristol-Myers Squibb to locate its research facility in the Kendall Sq. innovation cluster affirms Alexandria Center at Kendall Sq.'s reputation as one of the world's most desirable locations for life science recruitment, innovation, and collaboration. The Alexandria Center at Kendall Square is an 11-acre, world-class urban campus with 1.6 million s/f of high-quality office and laboratory space. Alexandria is the dominant life science owner and operator in its Greater Boston cluster with 5.2 million s/f of high-quality laboratory and office space (including development and redevelopment assets) located adjacent to world-renowned academic medical research centers. Alexandria currently serves over 100 life science and related client tenants in its Greater Boston cluster. "Bristol-Myers Squibb is one of the world's most respected biopharmaceutical companies because it continues to be a leading pioneer in identifying innovative treatments for serious diseases," said Joel Marcus, chairman, chief executive officer, and founder of Alexandria Real Estate. "We are truly honored to partner with Bristol-Myers Squibb, and welcome its top-notch R&D team to its new home in our Cambridge Kendall Square innovation cluster." The 100 Binney St. location will provide Bristol-Myers Squibb with mission critical adjacency to the vibrant life science community and its deep talent pool in Cambridge, also strengthening the ability of Bristol-Myers Squibb to recruit and retain top talent. The Cambridge Kendall Sq. innovation cluster is known for its dense concentration of pharmaceutical and biotechnology companies, highly collaborative and innovative academic institutions including Massachusetts Institute of Technology (MIT), and a strong venture capital presence. This flagship location, at the intersection of Binney and Second Sts., will feature innovative architecture that will be paired with glass facades and urban skyline views designed at the forefront of sustainability. 100 Binney will also include underground parking garages with car-share services, on-site covered bike parking, as well as excellent access to the Green and Red Lines, MBTA stops, and EZRide shuttle service. The amenity-rich retail and fitness facilities at the Alexandria Center at Kendall Sq. provide leading life science entities with a unique opportunity to drive productivity, accelerate innovation, and recruit and retain the brightest scientific talent.